FDA Approval: Novel Formulation for Treatment of Schizophrenia

September 11, 2024

Driving FDA Approvals with Precision and Speed

Discover how CRC’s expertise in clinical trial management supported the FDA approval of a novel formulation for schizophrenia treatment. Download the full case study to explore the challenges faced, proactive solutions implemented, and the strategic approach that delivered results on time and on budget.

December 18, 2024
Since 2018, more than 30 drugs with the potential to impair driving ability have been approved without a dedicated driving study, despite clearly meeting the FDA criteria for such studies based on a conservative application of these criteria.
October 10, 2024
Celebrating Progress in Mental Health Care
October 1, 2024
Proactive Mitigation to Support Program Success
Show More